Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6390194 | 1.00 | NPC1 (0.45) | NPC1RAB9ASMN1; SMN2POLBP2RX7 | |
| SCHEMBL6388874 | 0.91 | SMN1; SMN2 (0.44) | NPC1RAB9ASMN1; SMN2POLBP2RX7 | |
| SCHEMBL6504984 | 0.91 | SMN1; SMN2 (0.44) | NPC1RAB9ASMN1; SMN2POLBP2RX7 | |
| SCHEMBL6387573 | 0.91 | SMN1; SMN2 (0.44) | NPC1RAB9ASMN1; SMN2POLBP2RX7 | |
| SCHEMBL6506450 | 0.86 | CHRM1 (0.41) | NPC1RAB9AP2RX7HPGDCHRM1 | |
| SCHEMBL6388703 | 0.83 | CCNA2 (0.41) | NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL6392368 | 0.83 | CCNA2 (0.41) | NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL6390900 | 0.83 | CCNA2 (0.41) | NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL6426489 | 0.79 | P2RX7 (0.43) | NPC1RAB9AP2RX7GAA | |
| SCHEMBL6499658 | 0.75 | CXCR2 (0.36) | NPC1RAB9ASMN1; SMN2POLBHCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| WO-2005075471-A2 | THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | BIOVITRUM AB (SE) | 2005-08-18 | — | — | WO | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
| WO-2005075471-A2 | THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | BIOVITRUM AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | NPC1 277/4885RAB9A 2649/4885SMN1; SMN2 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.